Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on developing CRISPR-based therapies. The company’s investigational in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s investigational ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical, and clinical development experience, along with its people, is helping set the standard for developing potential new classes of medicine.